Format

Send to

Choose Destination
  • Showing results for peri interventional management of novel oral anticoagulants in daily care results from the prospective dresden noac registry. Your search for Peri-interventionalmanagement of novel oral anticoagulants in daily care: results fromthe prospective Dresden NOAC registry retrieved no results.
Eur Heart J. 2014 Jul 21;35(28):1888-96. doi: 10.1093/eurheartj/eht557. Epub 2014 Jan 6.

Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry.

Author information

1
Center for Vascular Medicine and Department of Medicine III, Division of Angiology, University Hospital 'Carl Gustav Carus' Dresden, Fetscherstrasse 74, 01307 Dresden, Germany jan.beyer@uniklinikum-dresden.de.
2
Center for Vascular Medicine and Department of Medicine III, Division of Angiology, University Hospital 'Carl Gustav Carus' Dresden, Fetscherstrasse 74, 01307 Dresden, Germany.
3
Institute for Medical Informatics and Biometry, Technical University Dresden, Dresden, Germany.

Abstract

AIMS:

Patients receiving novel oral anticoagulants (NOACs) frequently undergo interventional procedures. Short half-lives and rapid onset of action allow for short periods of NOAC interruption without heparin bridging. However, outcome data for this approach are lacking. We evaluated the peri-interventional NOAC management in unselected patients from daily care.

METHODS AND RESULTS:

Effectiveness and safety data were collected from an ongoing, prospective, non-interventional registry of >2100 NOAC patients. Outcome events were adjudicated using standard event definitions. Of 2179 registered patients, 595 (27.3%) underwent 863 procedures (15.6% minimal, 74.3% minor, and 10.1% major procedures). Until Day 30 ± 5 post-procedure, major cardiovascular events occurred in 1.0% of patients [95% confidence interval (95% CI) 0.5-2.0] and major bleeding complications in 1.2% (95% CI 0.6-2.1). Cardiovascular and major bleeding complications were highest after major procedures (4.6 and 8.0%, respectively). Heparin bridging did not reduce cardiovascular events, but led to significantly higher rates of major bleeding complications (2.7%; 95% CI 1.1-5.5) compared with no bridging (0.5%; 0.1-1.4; P = 0.010). Multivariate analysis demonstrated diabetes [odds ratio (OR) 13.2] and major procedures (OR 7.3) as independent risk factors for cardiovascular events. Major procedures (OR 16.8) were an independent risk factor for major bleeding complications. However, if major and non-major procedures were separately assessed, heparin bridging was not an independent risk factor for major bleeding.

CONCLUSION:

Continuation or short-term interruption of NOAC is safe strategies for most invasive procedures. Patients at cardiovascular risk undergoing major procedures may benefit from heparin bridging, but bleeding risks need to be considered.

KEYWORDS:

Apixaban; Bridging; Dabigatran; Invasive procedures; Oral anticoagulants; Rivaroxaban

PMID:
24394381
DOI:
10.1093/eurheartj/eht557
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center